Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis

British Journal of Dermatology

Volumn 151, Issue 3, 2004, Pages 656-662

  Vidal, David ^a   Matias Guiu X ^b   Alomar, A ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

Author keywords

Apoptotic index; Basal cell carcinoma; Bcl 2; Imiquimod

Indexed keywords

BIOTIN; DEOXYURIDINE TRIPHOSPHATE DERIVATIVE; DNA NUCLEOTIDYLEXOTRANSFERASE; IMIQUIMOD; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; BASAL CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SKIN BIOPSY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, BASAL CELL; CELL DIVISION; DOUBLE-BLIND METHOD; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 4944235951     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.06094.x     Document Type: Article

References (35)

1. Beutner KR, Geisse JK, Helman D et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41: 1002-7.
2. Marks R, Gebauer K, Shumack S et al. Imiquimod 5% cream in the treatment of superficial BCC: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44: 807-13.
3. Geisse JK, Rich P, Pandya A et al. Imiquimod 5% cream for the treatment of superficial BCC: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002; 47: 390-8.
4. Shumack S, Robinson J, Kossard S et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular BCC: comparison of dosing regimens. Arch Dermatol 2002; 138: 1165-71.
5. Sterry W, Herrera E, Takwale A et al. Imiquimod 5% cream for the treatment of superficial and nodular BCC: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002; 147: 1227-36.
6. Barnetson R, Halliday G, Satchell A et al. Cell infiltrates in BCC tumors after treatment with imiquimod 5% cream. J Eur Acad Dermatol Venereol 2002; 16 (Suppl. 1): 151.
7. Buechner SA. Intralesional interferon alfa-2b in the treatment of basal cell carcinoma. Immunohistochemical study on cellular immune reaction leading to tumor regression. J Am Acad Dermatol 1991; 24: 731-4.
8. Rodriguez-Villanueva J, McDonnell TJ. Induction of apoptotic cell death in non-melanoma skin cancer by interferon-alpha. Int J Cancer 1995; 61: 110-14.
9. Buechner SA, Wernli M, Harr T et al. Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide. J Clin Invest 1997; 100: 2691-6.
10. Raskin C. Apoptosis and cutaneous biology. J Am Acad Dermatol 1997; 36: 885-96.
11. Bold RJ, Termuhlen PM, McConkey DJ. Apoptosis, cancer and cancer therapy. Surg Oncol 1997; 6: 133-42.
12. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.
13. Baima B, Sticherling M. How specific is the TUNEL reaction? An account of a histochemical study on human skin. Am J Dermatopathol 2002; 24: 130-4.
14. Kerr JFR, Searle J. A suggested explanation for the paradoxically slow growth rate of basal-cell carcinomas that contain numerous mitotic figures. J Pathol 1972; 107: 41-4.
15. Mooney EEJ, Ruis Peris JM, O'Neill A. Apoptotic and mitotic indices in malignant melanoma and basal cell carcinoma. J Clin Pathol 1995; 48: 242-4.
16. Verhaegh MEJM, Sanders CJG, Arends JW et al. Expression of the apoptosis-suppressing protein Bcl-2 in non-melanoma skin cancer. Br J Dermatol 1995; 132: 740-4.
17. Ramdial PK, Madaree A, Reddy R et al. Bcl-2 protein expression in aggressive and non-aggressive basal cell carcinomas. J Cutan Pathol 2000; 27: 283-91.
18. Tilli CM, Stavast-Koey AJ, Ramaekers FC et al. Bax expression and growth behavior of basal cell carcinomas. J Cutan Pathol 2002; 29: 79-87.
19. Barrett TL, Smith KJ, Hodge JJ et al. Immunohistochemical nuclear staining for p53, PCNA, and Ki67 in different histologic variants of basal cell carcinoma. J Am Acad Dermatol 1997; 37: 430-7.
20. Healy E, Angus B, Lawrence CM et al. Prognostic value of Ki67 antigen expression in basal cell carcinomas. Br J Dermatol 1995; 133: 737-41.
21. McNutt NS, Saenz-Santamaria C, Volkenandt M et al. Abnormalities of p53 protein expression in cutaneous disorders. Arch Dermatol 1994; 130: 225-32.
22. Weedon D. Tumors of the epidermis. Basal cell carcinoma. In: Skin Pathology (Weedon D, ed.), 1st edn. London: Churchill Livingstone, Harcourt Publishers, 1997; 647-51.
23. Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol 2002; 147: 41-7.
24. Rippey JJ. Why classify basal cell carcinomas? Histopathology 1998; 32: 393-8.
25. Abdelsayed RA, Guijarro-Rojas M, IbrahImiq NA et al. Immunohistochemical evaluation of basal cell carcinoma and trichepithelioma using Bcl-2, Ki767, PCNA, and p53. J Cutan Pathol 2000; 27: 169-75.
26. Al Sader MH, Doyle E, Kay E et al. Proliferation indexes-a comparison between cutaneous basal and squamous cell carcinomas. J Clin Pathol 1996; 49: 549-51.
27. von Stamm U, Brocker EB, von Depka Prondzinski M et al. Effects of systemic interferon-alpha (IFN-alpha) on the antigenic phenotype of melanoma metastases. EORTC melanoma group cooperative study No 18852. Melanoma Res 1993; 3: 173-80.
28. Caraglia M, Passeggio A, Beninati S et al. Interferon α2 recombinant and epidermal growth factor modulate proliferation and hypusine synthesis in human epidermoid cancer KB cells. Biochem J 1997; 324(Pt 3): 737-41.
29. Auepemkiate S, Boonyaphiphat P, Thongsuksai P. P53 expression related to the aggressive infiltrating histopathological feature of basal cell carcinoma. Histopathology 2002; 40: 568-73.
30. Wikonkal NM, Berg RJ, van Haselen CW et al. Bcl-2 vs p53 protein expression and apoptotic rate in human nonmelanoma skin cancers. Arch Dermatol 1997; 133: 599-602.
31. Schon M, Bong AB, Drewniok C et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95: 1138-49.
32. Raisova M, Hossini AM, Eberle J et al. The bax/bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol 2001; 117: 333-40.
33. Urosevic M, Maier T, Benninghoff B et al. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003; 139: 1325-32.
34. Dummer R, Urosevic M, Kempf W et al. Imiquimod in basal cell carcinoma: how does it work? Br J Dermatol 2003; 149 (Suppl. 66): 57-8.
35. Berman B, Sullivan T, De Araujo T et al. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br J Dermatol 2003; 149 (Suppl. 66): 59-61.